NEWS CENTER

Position:

Group Announcement

Media reports

Group News

New products inject new momentum; Shijiazhuang No.4 Pharmaceutical is fully motivated and making a vigorous sprint toward the third quarter.

Category:

Media reports

Time：2022-09-16

On September 16, the formulation production workshop of Shijiazhuang Siyao Group, located in the Shijiazhuang High-tech Zone, was bustling with a lively and busy atmosphere. Employees were working at full speed to meet production targets and fulfill orders, making every effort to achieve the third-quarter goals.

New products inject new momentum; Shijiazhuang No.4 Pharmaceutical is fully motivated and making a vigorous sprint toward the third quarter.

On September 16, the formulation production workshop of Shijiazhuang Siyao Group, located in the Shijiazhuang High-tech Zone, was bustling with a lively and busy atmosphere. Employees were working wholeheartedly to ramp up production, meet orders, and strive to achieve the third-quarter targets.

“With years of careful preparation, our four pharmaceutical companies have finally begun to reap the rewards of their hard work,” said Su Xuejun, Chairman of Shijiazhuang Four Pharmaceutical Group, with delight. “Since September, we’ve received approval for three new products one after another, bringing the total number of approvals we’ve secured so far this year to 29.” Among the newly approved products are the methylcobalamin injection, which has just passed the consistency evaluation, and the bunacline tablets—the first domestically approved product of their kind—continuously injecting new momentum into the company’s high-quality development.

In Workshop 104 of Siyao Pharmaceutical, the filling equipment for aqueous injection preparations is running at a rapid pace. Products, neatly arranged and uniformly spaced, swiftly flow off the conveyor belt, “lining up” and rapidly heading toward the packaging process.

“Our workshop is currently tasked with producing 5 million vials of bromhexine hydrochloride injection—the winning bid product in the national centralized procurement. To ensure timely delivery in the fourth quarter, the company has promptly adjusted its production resource allocation, and our workshop is operating at full capacity to stock up on supplies and do everything possible to meet market demand,” said Wang Chao, director of Workshop 104.

“In this year’s seventh round of national centralized procurement, Sihua Pharmaceutical’s two new products—the bromhexine hydrochloride injection and the cefaclor dry suspension—won bids with a significant advantage. These products will be marketed in provinces and regions including Shanghai, Zhejiang, Hebei, and Xinjiang,” Su Xuejun told reporters. Currently, Sihua Pharmaceutical has secured bids for eight varieties across 11 specifications in the national centralized procurement, which has played a tremendous role in boosting market share, optimizing product portfolio structure, and comprehensively enhancing the market influence of Sihua’s pharmaceutical preparations. In addition to the rapid market entry and substantial volume growth achieved by the products that have won bids in the national centralized procurement, Sihua Pharmaceutical has also seized market opportunities and launched several new products—including terbutaline sulfate solution for nebulization, dexmedetomidine hydrochloride injection, bunacline tablets, and rosuvastatin calcium tablets—that are unleashing considerable market potential. The sales proportion of these new products is steadily increasing. From January to August this year, Sihua Pharmaceutical’s sales revenue and profits and taxes both recorded double-digit growth.

“Continuously focus on the high-end segments of both the industrial chain and the innovation chain, steadily strengthening our development momentum.” Following this approach, Siyao places great emphasis on the development and innovation of pioneering new products, vigorously promoting the R&D of a number of critical technologies that have long been “bottlenecked.” As a result, innovative achievements have been continuously emerging. To date, Siyao has obtained 29 product approvals this year, including 19 formulation approvals and 10 active pharmaceutical ingredient approvals. Among these, four formulation products—such as Acetaminophen Mannitol Injection and Azithromycin Dry Suspension—have become the first domestically approved by any Chinese pharmaceutical company. These innovative products are providing a powerful engine for the company’s competitive advancement and continuously empowering its industrial chain to move toward the high-end segments of the value chain.

With full vigor and determination, we’re accelerating development and striving hard to achieve outstanding results. Leveraging the favorable industrial policies of Shijiazhuang City and the benefits brought by enterprises’ innovative development, the entire Four Pharmaceutical Group is making a vigorous sprint toward the third quarter, laying a solid foundation for completing this year’s targets. Su Xuejun stated that, in the next phase, Four Pharmaceutical will continue to embrace the spirit of seizing every moment and striving for excellence in everything we do, speeding up the pace of production organization, market supply assurance, scientific research and development, and project construction. With new achievements in innovative development, we will endeavor to take the lead, set an example, and make significant contributions to helping the city’s biopharmaceutical industry break through first and achieving the goal of exceeding one trillion yuan in total economic output.

Reposted from: Shijiazhuang Daily

Keywords:

Check in at the Green Factory and Uncover the Secrets of Sustainable Development—Shijiazhuang No.4 Pharmaceutical Group Is Walking Toward “Green” with Vibrant Greenery.

Shijiazhuang Fourth Pharmaceutical Group Bosheng Medical Devices: Empowering Industry Optimization While Simultaneously Pursuing Intelligent Upgrades and Green Development.

Check in at the Green Factory and Uncover the Secrets of Sustainable Development—Shijiazhuang No.4 Pharmaceutical Group Is Walking Toward “Green” with Vibrant Greenery.

Shijiazhuang Fourth Pharmaceutical Group Bosheng Medical Devices: Empowering Industry Optimization While Simultaneously Pursuing Intelligent Upgrades and Green Development.